Top Stories
Neurotech Pharmaceuticals' cell therapy Encelto is the only FDA-approved treatment for macular telangiectasia type 2.
The approval was based on data from the Phase III REPLENISH study, which demonstrated a roughly 41% remission rate for Cosentyx in patients with the inflammatory rheumatic disease.
Boston-based AI Proteins will create novel therapeutic candidates from scratch against undisclosed targets.
The success of the TYK2/JAK1 inhibitor in the CLARITY programme for non-infectious uveitis comes shortly after it was approved by the FDA for dermatomyositis.
Deborah Waterhouse, the current CEO of ViiV Healthcare, will assume the role of chief executive and managing director at CSL from Feb. 1 next year.
Conference News
New data include two-year Phase 3 efficacy and safety update, and quality of life analysis for pimicotinib in tenosynovial giant cell tumorFirst presentation of median overall survival results for inv...
London, UK, 22 October 2026 - Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain ...
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placeboLower NfL and GFAP levels provide objective, compleme...
FirstWord will be speaking with a leading expert about Phase IIa TARGET-CD data for AbbVie's ABBV-466, and how the IL-23/α4β7 and other dual-targeting therapies are likely to change the treatment of IBD.
JERSEY CITY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for...
